Author/Authors :
Casella, Giovanni Medical Department - Desio Hospital - Desio (Monza e Brianza), Italy , Viganò, Davide Medical Department - Desio Hospital - Desio (Monza e Brianza), Italy , Romano Settanni, Carlo Gastroenterology and Hepatology Section - Department of Medicine - University of Perugia Medical School, Italy , Morelli, Olivia Gastroenterology and Hepatology Section - Department of Medicine - University of Perugia Medical School, Italy , Villanacci, Vincenzo Institute of Pathology - Spedali Civili di Brescia, Brescia, Italy , Baldini, Vittorio Medical Department - Desio Hospital - Desio (Monza e Brianza), Italy , Bassotti, Gabrio Gastroenterology and Hepatology Section - Department of Medicine - University of Perugia Medical School, Italy
Abstract :
Celiac disease is characterized by a gluten-induced damage of the small bowel in sensitive individuals that may cause
malabsorption. Non-intestinal inflammatory diseases may trigger immunologic gluten intolerance in susceptible people
and the HCV virus may be considered as a suitable candidate. Interferon therapy could precipitate symptom onset in
subjects with silent celiac disease. In fact, symptoms such as diarrhea, anemia, and weight loss may occur during
interferon therapy and are associated with serological positivity of anti-tranglutaminase antibodies. To date, considering
the available literature data, it is very difficult to support a firm association between HCV chronic hepatitis and celiac
disease. Thus, such a serological screening in HCV patients before starting interferon therapy should not be
recommended. However, serology for celiac disease must be considered in patients who develop diarrhea and/or weight
loss during such therapy.
Keywords :
Celiac disease , Chronic hepatitis , HCV virus , Interferon therapy , Liver disease